MDRNA is conducting a study with Pfizer to evaluate its proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi).
MDRNA will formulate Pfizer’s oligonucleotides in DiLA2 formulations for in vivo preclinical evaluation to be conducted by Pfizer.
MDRNA will also design and synthesise UsiRNAs for targets identified by Pfizer.
UsiRNAs can enhance RNAi-based therapeutics due to their high potency and improved drug-like properties.
The DiLA2 Delivery Platform can create novel liposomal delivery systems based on di-alkylated amino acids.
Share this article
